Logo

Pharming Receive EMA's Approval to Establish New Facility for Manufacturing Ruconest (conestat alfa)

Share this

Pharming Receive EMA's Approval to Establish New Facility for Manufacturing Ruconest (conestat alfa)

Shots:

  • The approval will increase the production capacity of Ruconest and allows Pharming to release the therapy manufactured at the facility during the approval process for commercialization in the EU
  • The news facility is expected to reduce the risk of short-term pressure on the supply of Ruconest in the EU market targeting the needs of patients with hereditary angioedema
  • Ruconest is a recombinant human C1 esterase inhibitor- approved to treat HAE attacks in the US- EU- Israel and South Korea with the expected approval for the establishment of its new facility in the US in H1’20

Click here to­ read full press release/ article | Ref: Pharming  | Image: Solebury Trout Access


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions